XRPC yields 13.92% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 6
Combined, XRPC + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of XRPC + ABBV for your $10,000?
XRPC seeks to provide direct exposure to the price of XRP, a decentralized digital asset designed for real-time payment and settlement via the XRP Ledger. All XRP tokens were created at launch in 2012. The calculation of the funds NAV is based on a benchmark provided by CoinDesk Indices, aggregating prices from major XRP trading platforms. XRP held by the Trust is stored at Gemini and BitGo, both private custodians insured by non-FDIC carriers. Unlike stocks or bonds, XRP ownership confers no company profits or income, and is only recorded on a decentralized ledger. The ETF advantage for investors is that they can access the market performance of XRP through their regular brokerage accounts, without needing to hold XRP directly or face related risks. The Trust does not use derivatives, loans, or leverage. The XRP Ledger uses a low-energy, consensus-based mechanism rather than mining, enabling fast, low-cost cross-border transactions.
Full XRPC Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.